EPLIN, a Marker for Human Cancer
EPLIN-based molecular reagents will prove useful because there are a limited number of biomarkers with proven utility for detection of breast and prostate cancer. EPLIN-based biomarkers can be used in conjunction with or independently of existing biomarkers to facilitate the diagnosis and prognosis of these cancers.
EPLIN-based molecular reagents can be used in cancer detection, prognosis, and therapy. The EPLIN gene can be used to determine how the expression of EPLIN is down-regulated in cancer cells.
UC researchers have discovered a gene encoding EPLIN. EPLIN cDNA has been cloned, completely sequenced, and tested to detect its expression in human cells and tissues. The EPLIN gene has been cloned to determine the structure of the EPLIN gene including the regulatory sequences for the expression of EPLIN. In addition, EPLIN has been bacterially expressed to generate polyclonal antibodies to detect the expression of EPLIN by immunoblotting, immunohistochemistry, and in situ immunofluorescence.
Patent Number: US6864066B1
Application Number: US2000658400A
Inventor: Chang, David D. | Maul, Raymond S.
Priority Date: 8 Sep 1999
Priority Number: US6864066B1
Application Date: 8 Sep 2000
Publication Date: 8 Mar 2005
IPC Current: C07K001447 | A61K003800
US Class: 4350691 | 4353201 | 435325 | 5360231 | 5360235 | 53602431
Assignee Applicant: The Regents of the University of California
Title: Epithelial protein lost in neoplasm (EPLIN)
Usefulness: Epithelial protein lost in neoplasm (EPLIN)
Summary: EPLIN nucleic acids, proteins are used in screening assays to detect molecules that specifically bind to EPLIN nucleic acids, proteins or derivatives (claimed) and thus have potential use as agonist or antagonist of EPLIN, in particular molecules that affect cell proliferation. Thus the assays are useful for screening molecules with potential utility as anticancer drugs or lead compounds for drug development. EPLIN nucleic acids, proteins are useful for detecting a cell proliferative disorder in a subject (claimed). The molecules are useful for prognosing, diagnosing, or monitoring various disease conditions and disorders affecting EPLIN expression or monitor the treatment of the above conditions. (II) is useful in gene therapy techniques for expressing EPLIN in vivo for ameliorating conditions associated with EPLIN. (II) is also useful in hybridization assays for detecting, prognosing, diagnosing, or monitoring conditions or disease states associated with aberrant changes in EPLIN expression and/or activity. EPLIN protein, or mRNA are useful as diagnostic reagents for diagnosing diseases or disorders involving over proliferation of cells in which case the levels of EPLIN protein is increased. EPLIN protein, or mRNA are also useful as diagnostic reagents for diagnosing or prognosing malignancy or hyperproliferative disorder in a subject, in which case the subject has decreased levels of EPLIN. (I) is useful as a marker that can be diagnostically, prognostically and therapeutically used over the course of a cell proliferative disorder associated with EPLIN.
Novelty: New tumor suppressor protein EPLIN, useful as a marker for diagnostic, prognostic and therapeutic applications over the course of cell proliferative disorders associated with EPLIN
Disease Diagnostic/Treatment
Cancer/Tumor
6864066
User Defined 1 Tech ID/UC Case 10140/1999-300-0 Related Cases 1999-300-0
EPLIN, a novel gene not previously described, encodes a protein expressed in human epithelial cells. EPLIN is of significant importance because its expression is diminished in many forms of human cancers including breast and prostate cancer. Restoring the expression of EPLIN in cancer cells antagonizes oncogenic transformation.
USA
